Citigroup
ORIC icon

Citigroup’s Oric Pharmaceuticals ORIC Stock Holding History

Citigroup’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$215K Sell
16,994
-137,155
-89% -$1.56M ﹤0.01% 3973
2025
Q4 		$1.26M Buy
154,149
+143,515
+1,350% +$1.65M ﹤0.01% 2984
2025
Q3 		$128K Sell
10,634
-21,915
-67% -$231K ﹤0.01% 4174
2025
Q2 		$330K Sell
32,549
-71,557
-69% -$480K ﹤0.01% 3840
2025
Q1 		$581K Buy
104,106
+32,312
+45% +$283K ﹤0.01% 3594
2024
Q4 		$579K Buy
71,794
+25,794
+56% +$237K ﹤0.01% 3729
2024
Q3 		$472K Buy
46,000
+18,510
+67% +$183K ﹤0.01% 3767
2024
Q2 		$194K Sell
27,490
-106,416
-79% -$953K ﹤0.01% 3888
2024
Q1 		$1.84M Buy
133,906
+127,343
+1,940% +$1.51M ﹤0.01% 2500
2023
Q4 		$60.4K Buy
6,563
+6,538
+26,152% +$47.3K ﹤0.01% 4436
2023
Q3 		$151 Sell
25
-11,599
-100% -$95K ﹤0.01% 5354
2023
Q2 		$90.2K Sell
11,624
-33,464
-74% -$190K ﹤0.01% 4297
2023
Q1 		$257K Buy
+45,088
New +$236K ﹤0.01% 3580
2022
Q4 		– Sell
-474
Closed -$2K – 5907
2022
Q3 		$2K Sell
474
-476
-50% -$1.91K ﹤0.01% 5514
2022
Q2 		$4K Sell
950
-4,992
-84% -$19.9K ﹤0.01% 5701
2022
Q1 		$32K Sell
5,942
-55,291
-90% -$498K ﹤0.01% 4929
2021
Q4 		$900K Buy
61,233
+34,680
+131% +$541K ﹤0.01% 3363
2021
Q3 		$556K Sell
26,553
-57,876
-69% -$1.17M ﹤0.01% 3533
2021
Q2 		$1.49M Sell
84,429
-4,308
-5% -$94.4K ﹤0.01% 2913
2021
Q1 		$2.17M Buy
88,737
+80,094
+927% +$2.53M ﹤0.01% 2435
2020
Q4 		$293K Buy
8,643
+5,891
+214% +$169K ﹤0.01% 4685
2020
Q3 		$69K Sell
2,752
-328
-11% -$7.81K ﹤0.01% 5377
2020
Q2 		$105K Buy
+3,080
New +$98.3K ﹤0.01% 5532

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Citigroup's ORIC Position: Q1 2026 in Review

Citigroup reduced its Oric Pharmaceuticals (ORIC) stake by 89% in Q1 2026, selling an estimated $1.56M and leaving 16,994 shares worth $215K. The position accounts for ﹤0.01% of the portfolio, ranked #3973.

Citigroup first reported a position in ORIC in Q2 2020 and has held it in 23 quarters since. The position peaked at $2.17M in Q1 2021. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Citigroup held 16,994 shares of Oric Pharmaceuticals worth $215K as of Q1 2026.
  • Citigroup sold 137,155 Oric Pharmaceuticals shares in Q1 2026, an estimated $1.56M.
  • Oric Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3973 holding.
  • Citigroup first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 23 quarters since.
  • Citigroup's Oric Pharmaceuticals position peaked at $2.17M in Q1 2021.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.